pSivida Release DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur 8482 FA for the Treatment of DME: related news

pSivida Release: DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur™ FA for the Treatment of DME

Home > Press > pSivida Release: DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur™ FA for the Treatment of DME

Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement

Alimera Sciences and pSivida Ltd (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that they have amended their license and collaboration agreement relating to Medidur™ FA, the companies' Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products. Alimera is increasing its equity in the future profits of Medidur FA from 50 to 80 percent in exchange for consideration of up to approximately US$78m to pSivida.

Insert Therapeutics to Initiate a Multinational Phase II Clinical Trial of Lead Drug Candidate IT-101 in Ovarian Cancer

PASADENA, Calif.--(BUSINESS WIRE)--April 17, 2008 - Insert Therapeutics, Inc., a majority owned subsidiary of Arrowhead Research Corporation (ARWR), announced today that it has filed with the U.S. Food and Drug Administration to initiate a Phase II clinical trial evaluating the safety and efficacy of its drug candidate IT-101 in patients with ovarian cancer. In women who receive a 2nd course of chemotherapy, nearly 75% will achieve some degree of disease stabilization. However, most will experience a recurrence of their cancer within 9 to 12 months after treatment. For these women, the current standard care is to "watch and wait" until disease progression occurs.

Paradox expands Europa Universalis III again

Paradox Interactive today announced a new expansion for Europa Universalis III. EU III: In Nomine, which requires Napoleon’s Ambition, is scheduled for a release before summer. “The idea for this expansion was born in our forums,� said producer and head of development, Johan Andersson. “We felt that the forum wishes for the next EU III expansion aligned with our visions for Europa Universalis III.�

Bilcare Global Clinical Supplies Forms Corporate Advisory Board

Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial services, has formed its first corporate Advisory Board. Bilcare Limited's Chairman and Managing Director Mohan Bhandari announced former Pfizer President John LaMattina, Ph.D., and Waterloo Institute of Nanotechnology Executive Director Arthur Carty, Ph.D., D.Sc., as the board's inaugural members. Dr. LaMattina will serve as its Chairman. The advisory board was created to provide the Bilcare GCS Senior Management Team with independent scientific industry expertise and insight to assist in the accomplishment of scientific and business objectives in support of the company's global mission. "The formation of our corporate Advisory Board is another major milestone in our mission to make Bilcare GCS the global leader in the clinical trial supplies arena," sai

Red Hat Enterprise Linux release 2.95 AS Beta (Taroon) Preview

IconRed Hat released the beta for their upcoming Red Hat Enterprise Linux (RHEL) line. The release is tagged release 2.95, Taroon. The next official release will probably be called RHEL release 3 (as usual, Red Hat does not confirm their upcoming release version and date).

Borderlands Sees Delay While Mafia II Gets Time Frame

March 11, 2008 - Borderlands, a sci-fi action RPG from Gearbox, previously set for a Q3 2008 release, has been delayed for a fiscal 2009 release date. In addition, it was announced that Mafia II, sequal to the previous mob-styled action game, will release within the fiscal 2009 time period. According to Take-Two (via Shacknews), Borderlands was delayed "in order to allow additional development time for this highly anticipated game and provide a better balance in the release of Take-Two's triple-A titles." That other triple-A title that Take-Two has up its sleeve is GTA IV, which is currently set for an April 28th release date in the US and an April 29th release date in all other territories.

Tui e Minisita ki he ngaue 'a e kakaii 'e tokoni ako fekau'aki mo e Copyrights

'Oku 'iai 'a e fiema'u ke fakatokanga'i ange 'a e mahu'inga 'o e malu'i e ngaahi totonu fakafo'ituitui mo e ngaahi totonu kehe ange, felave'i mo e totonu 'a e kau fa'u hiva, fa'u tohi, fa'u ta'anga, fa'u polokalama, kau faiva, tau tefito ki he ngaahi polokalama pe ko ha fa'ahinga polokalama pee 'oku nau fa'uu.

Suven Life bags 2 patents in Eurasia

Suven Life Sciences Ltd has been granted two product patents in Eurasia for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents (nos. 009193 and 009367) are valid till 2023 in all contracting countries such as Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan. “We are very pleased by the grant of these patents to Suven for our drug candidates that are being developed for CNS disorders, which target an $18 billion potential market opportunity globally,� Mr Venkat Jasti, Chief Executive Officer of Hyderabad-based Suven Life Sciences, said in a release. Products out of these inventions, which were in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage.

Urigen Announces US Patent Office Notice of Allowance of Claims for URG101

BURLINGAME, Calif.--(Business Wire)-- Urigen Pharmaceuticals, Inc. (OTCBB: URGP), www.urigen.com announced that the U.S. Patent and Trademark Office issued a notice of allowance for claims for the first patent application for URG101, an investigational, bladder instillation for the treatment of Painful Bladder Syndrome/Interstitial Cystitis (PBS). These claims broadly cover URG101 and its use in the treatment of PBS by administering a glycosaminoglycan (such as heparin) and a local anesthetic. Urigen recently closed a Phase II study of URG101 due to positive, statistically significant results at interim analysis with 50 percent patient enrollment. The Phase II study was a multi-center, double-blind, placebo-controlled, crossover designed clinical trial of URG101 in patients with PBS.

Sony again delays "Home" virtual world for PlayStation 3; now says release is 2nd half of year

TMCNet: Sony again delays "Home" virtual world for PlayStation 3; now says release is 2nd half of year

New Release of Java Math Expression Parser 3.2 Available for Trial Now

JEP, Java library for parsing and evaluating mathematical expressions is available in new release Jep 3.2. This package allows users to enter an arbitrary formula as a string and evaluate it. JEP supports user defined variables, constants, and functions. A number of common mathematical functions and constants are also included.

Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned

Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned

The Mint Linux team made a final release this week for its community edition distribution, while Mythbuntu and Ubuntu both added new alphas in on the way to Hardy Heron's release in April. People power transforms the web in next online revolutio

The Mint Linux team made a final release this week for its community edition distribution, while Mythbuntu and Ubuntu both added new alphas in on the way to Hardy Heron’s release in April.

Trouble in trialville: Plans for post-DES clopidogrel trial get bogged down over trial design, leadership

Chicago, IL - Almost 16 months after an FDA hearing into drug-eluting stent (DES) safety emphasized the need for a randomized clinical trial to determine, once and for all, the optimal duration of clopidogrel (Plavix, Sanofi-Aventis) plus aspirin after DES implantation, researchers, government agencies, and industry sponsors cannot agree on how it should move ahead.

Adobe fires across Apple's bow with Lightroom 2.0 beta

Apple certainly jumped ahead of Lightroom with the release of Aperture 2.1 and its plug-in architecture. This morning, though, Adobe fired back with a Lightroom 2.0 beta. Though Adobe hasn't announced a release date, the beta is scheduled to expire on August 31. However, Adobe wasn't afraid to lob one at Apple when describing its release schedule: "One thing we can say, however, is that we plan to continue with a more aggressive release schedule than we’ve seen from Apple, which took over two years between release of Aperture 1.0 and 2.0."

OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

Suven Life gets European patent

Suven Life Sciences Ltd secured a product patent for its clinical candidate being developed for the central nervous system (CNS) disorders in the treatment of cognitive impairment from the European Patent Office (EPO). The patent (EP 1581492) has been granted to SUVN-502 which is valid until June 2023. `Granting of this patent to our clinical candidate is more timely and relevant now that the candidate is entering into clinical trials,'' Mr Venkat Jasti, Chief Executive Officer, Suven Life Sciences said in a release. - Our Bureau

::: OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

Inclinix Announces New Patent for Expert System Platform

WILMINGTON, N.C., March 10 /PRNewswire/ -- Inclinix, Inc., an enrollment contract research organization (CRO) and provider of clinical trial recruitment solutions, announced today that it has received a patent for its Expert System Platform (ESP). ESP is a software system that guides interview questions during patient qualification for clinical trials of new drugs or medical devices. Inclinix advertises to recruit patients into clinical trials. Respondents to Inclinix advertising answer questions on a Web site or when interacting via phone with Inclinix TeleMEDICINE(TM) Contact Center representatives. The questions posed to respondents determine if the respondents fit the inclusion and exclusion criteria from the trial sponsor, usually a pharmaceutical company.

Mandrake Linux 10 Preview

IconMandrake Linux 10.0-preview edition pretty much defines the shape of things to come in Linux land in 2004. With Kernel 2.6, KDE 3.2 beta and XFree86 4.4 beta, it doesn't leave much to be desired. This article refers to cooker snapshot as of December 31, 2003. Please note that this release is not a beta release. This is not even an alpha release. Its just something put together to show what we can expect from Mandrake 10.0. This release comes on only two CDs so some of the packages are missing. And as there are bound to be lot of bugs in this kind of release, I'll be concentrating more on the usability aspect. So let's see if it is worth drooling over.

Phase One, Mamiya introduce new digital camera platform

Phase One and Mamiya Digital Imaging have unveiled what they call the world’s most flexible, open medium format digital camera platform. Known as the Phase One 645 Camera or the Mamiya 645AFDIII, the co-developed platform will be sold by Phase One and Mamiya.

Phase One and Mamiya Digital Imaging Introduce the World's Most Flexible Open Medium Format Digital Camera Platform

TOKYO (Business Wire) -- Phase One A/S and Mamiya Digital Imaging Co., Ltd. today unveiled the world's most flexible, open medium format digital camera platform. Known as the Phase One 645 Camera or the Mamiya 645AFDIII, the co-developed platform will be sold exclusively by Phase One and Mamiya respectively.

Phase One and Mamiya Introduce 'World's Most Flexible' Open Medium-Format Digital Camera Platform

PHOTO IMAGING EXPO, TOKYO, March 19, 2008 — Phase One A/S and Mamiya Digital Imaging Co., Ltd. unveiled "the world’s most flexible, open medium format digital camera platform." Known as the Phase One 645 Camera or the Mamiya 645AFDIII, the co-developed platform will be sold exclusively by Phase One and Mamiya respectively.

Phase One and Mamiya Digital Imaging Introduce the World's Most Flexible Open Medium Format Digital Camera Platform

PHOTO IMAGING EXPO, TOKYO, 19 March 2008 -- Phase One A/S and Mamiya Digital Imaging Co., Ltd. today unveiled the world's most flexible, open medium format digital camera platform. Known as the Phase One 645 Camera or the Mamiya 645AFDIII, the co-developed platform will be sold exclusively by Phase One and Mamiya respectively.

Search took 0.44 seconds.